| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2024 | 193 | 4.530 |
Why?
|
| Kidney Tubules | 12 | 2024 | 39 | 4.250 |
Why?
|
| MicroRNAs | 11 | 2024 | 518 | 3.780 |
Why?
|
| Epithelial Cells | 20 | 2024 | 434 | 3.360 |
Why?
|
| Exosomes | 8 | 2024 | 126 | 3.130 |
Why?
|
| HIV-1 | 21 | 2024 | 755 | 3.040 |
Why?
|
| Kidney Tubules, Proximal | 9 | 2024 | 34 | 2.710 |
Why?
|
| Diabetic Nephropathies | 9 | 2024 | 78 | 2.670 |
Why?
|
| Reperfusion Injury | 5 | 2023 | 58 | 2.320 |
Why?
|
| RNA, Messenger | 17 | 2021 | 1271 | 2.280 |
Why?
|
| Macrophages | 7 | 2024 | 529 | 2.170 |
Why?
|
| Kidney Diseases | 7 | 2020 | 172 | 2.140 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 9 | 2024 | 16 | 1.950 |
Why?
|
| Cytidine Deaminase | 12 | 2014 | 36 | 1.840 |
Why?
|
| Fibrosis | 13 | 2024 | 169 | 1.830 |
Why?
|
| Inflammation | 13 | 2023 | 758 | 1.820 |
Why?
|
| Kidney Failure, Chronic | 6 | 2020 | 242 | 1.790 |
Why?
|
| Nephritis, Interstitial | 5 | 2018 | 7 | 1.740 |
Why?
|
| Angiotensin II | 6 | 2024 | 102 | 1.690 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2024 | 88 | 1.670 |
Why?
|
| Mice | 28 | 2024 | 6644 | 1.220 |
Why?
|
| Podocytes | 5 | 2024 | 37 | 1.220 |
Why?
|
| Kidney | 11 | 2023 | 372 | 1.190 |
Why?
|
| Biphenyl Compounds | 4 | 2011 | 53 | 1.190 |
Why?
|
| Tetrazoles | 4 | 2011 | 46 | 1.170 |
Why?
|
| Cells, Cultured | 18 | 2022 | 1621 | 1.160 |
Why?
|
| Humans | 77 | 2024 | 43102 | 1.150 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 1869 | 1.130 |
Why?
|
| Male | 43 | 2024 | 23409 | 1.090 |
Why?
|
| Signal Transduction | 9 | 2024 | 2157 | 1.090 |
Why?
|
| Renal Dialysis | 4 | 2022 | 131 | 1.080 |
Why?
|
| Calcinosis | 2 | 2022 | 62 | 1.080 |
Why?
|
| Animals | 41 | 2024 | 16992 | 1.070 |
Why?
|
| Kidney Glomerulus | 3 | 2021 | 86 | 1.070 |
Why?
|
| Cell Line | 18 | 2024 | 1410 | 1.060 |
Why?
|
| Uric Acid | 2 | 2020 | 29 | 1.040 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2019 | 97 | 1.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2011 | 41 | 1.010 |
Why?
|
| Immediate-Early Proteins | 5 | 2007 | 49 | 0.990 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2021 | 131 | 0.970 |
Why?
|
| Carrier Proteins | 4 | 2018 | 321 | 0.960 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2007 | 100 | 0.960 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 1596 | 0.940 |
Why?
|
| Nephroblastoma Overexpressed Protein | 2 | 2017 | 3 | 0.930 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 5 | 2015 | 19 | 0.910 |
Why?
|
| Receptors, LDL | 3 | 2015 | 42 | 0.910 |
Why?
|
| Membrane Proteins | 6 | 2024 | 561 | 0.880 |
Why?
|
| Virus Assembly | 8 | 2015 | 44 | 0.880 |
Why?
|
| Macrophage Activation | 3 | 2021 | 61 | 0.880 |
Why?
|
| Telomere | 2 | 2024 | 59 | 0.870 |
Why?
|
| Lectins, C-Type | 2 | 2021 | 37 | 0.830 |
Why?
|
| Diaphragm | 2 | 2022 | 11 | 0.820 |
Why?
|
| DNA, Complementary | 1 | 2024 | 196 | 0.820 |
Why?
|
| Viral Envelope Proteins | 2 | 2015 | 91 | 0.810 |
Why?
|
| Hexokinase | 1 | 2023 | 10 | 0.800 |
Why?
|
| Lysine | 2 | 2016 | 119 | 0.800 |
Why?
|
| Disease Progression | 5 | 2024 | 667 | 0.760 |
Why?
|
| Virion | 4 | 2014 | 75 | 0.750 |
Why?
|
| Virus Replication | 8 | 2024 | 318 | 0.750 |
Why?
|
| Mice, Knockout | 9 | 2024 | 1035 | 0.750 |
Why?
|
| Cytosine Deaminase | 3 | 2014 | 7 | 0.740 |
Why?
|
| Actins | 10 | 2016 | 164 | 0.740 |
Why?
|
| Mitochondria | 2 | 2018 | 523 | 0.730 |
Why?
|
| Transcription Factor RelA | 2 | 2021 | 42 | 0.720 |
Why?
|
| Interleukin-1beta | 3 | 2018 | 75 | 0.720 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 33 | 0.710 |
Why?
|
| China | 8 | 2024 | 229 | 0.710 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2021 | 15 | 0.710 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.670 |
Why?
|
| Glomerular Filtration Rate | 3 | 2016 | 147 | 0.660 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2021 | 72 | 0.650 |
Why?
|
| Transfection | 9 | 2016 | 532 | 0.650 |
Why?
|
| NF-kappa B | 4 | 2021 | 358 | 0.650 |
Why?
|
| Connective Tissue Growth Factor | 6 | 2012 | 19 | 0.640 |
Why?
|
| Autophagy | 1 | 2021 | 140 | 0.640 |
Why?
|
| Muscle Weakness | 1 | 2019 | 7 | 0.630 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 161 | 0.630 |
Why?
|
| Mutation | 4 | 2024 | 1177 | 0.620 |
Why?
|
| Gene Products, vif | 5 | 2006 | 6 | 0.620 |
Why?
|
| Albuminuria | 3 | 2015 | 78 | 0.610 |
Why?
|
| Middle Aged | 18 | 2024 | 12222 | 0.610 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2019 | 13 | 0.590 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2012 | 652 | 0.580 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 220 | 0.580 |
Why?
|
| Down-Regulation | 6 | 2021 | 456 | 0.580 |
Why?
|
| Regeneration | 1 | 2018 | 32 | 0.580 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 163 | 0.560 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2018 | 4 | 0.550 |
Why?
|
| Collagen | 1 | 2019 | 181 | 0.550 |
Why?
|
| Thioredoxins | 1 | 2018 | 41 | 0.540 |
Why?
|
| Ureteral Obstruction | 4 | 2021 | 16 | 0.540 |
Why?
|
| Aorta | 2 | 2016 | 198 | 0.540 |
Why?
|
| Nephrectomy | 3 | 2020 | 30 | 0.540 |
Why?
|
| Rats | 10 | 2021 | 3735 | 0.540 |
Why?
|
| Mesangial Cells | 1 | 2017 | 9 | 0.540 |
Why?
|
| Female | 24 | 2024 | 24698 | 0.540 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 56 | 0.530 |
Why?
|
| Homeostasis | 1 | 2018 | 192 | 0.530 |
Why?
|
| Ubiquitin | 2 | 2016 | 81 | 0.520 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 95 | 0.500 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2016 | 3 | 0.500 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 131 | 0.500 |
Why?
|
| Adult | 16 | 2021 | 13872 | 0.500 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 10 | 0.490 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2015 | 3 | 0.480 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 146 | 0.480 |
Why?
|
| Gene Expression | 6 | 2012 | 701 | 0.480 |
Why?
|
| Cost of Illness | 1 | 2016 | 98 | 0.470 |
Why?
|
| Health Care Costs | 1 | 2016 | 91 | 0.470 |
Why?
|
| Population Surveillance | 2 | 2016 | 246 | 0.460 |
Why?
|
| Apolipoproteins E | 2 | 2013 | 138 | 0.460 |
Why?
|
| Insurance Coverage | 1 | 2016 | 110 | 0.460 |
Why?
|
| Endothelial Cells | 2 | 2016 | 329 | 0.450 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 185 | 0.450 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 532 | 0.450 |
Why?
|
| Serum Albumin | 1 | 2015 | 59 | 0.450 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 228 | 0.440 |
Why?
|
| Adhesins, Bacterial | 1 | 2014 | 21 | 0.430 |
Why?
|
| Atherosclerosis | 2 | 2013 | 169 | 0.430 |
Why?
|
| Gene Expression Regulation | 6 | 2021 | 1070 | 0.430 |
Why?
|
| Glucose | 1 | 2016 | 244 | 0.430 |
Why?
|
| Endopeptidases | 1 | 2014 | 64 | 0.430 |
Why?
|
| Nephritis | 3 | 2019 | 7 | 0.420 |
Why?
|
| Proteinuria | 4 | 2020 | 56 | 0.420 |
Why?
|
| Hyperuricemia | 1 | 2014 | 14 | 0.420 |
Why?
|
| Cell Membrane | 2 | 2014 | 403 | 0.420 |
Why?
|
| Vagina | 1 | 2014 | 89 | 0.410 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2013 | 3 | 0.410 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2013 | 5 | 0.410 |
Why?
|
| RNA Interference | 5 | 2021 | 247 | 0.410 |
Why?
|
| Foam Cells | 1 | 2013 | 16 | 0.410 |
Why?
|
| Aged | 12 | 2024 | 8214 | 0.410 |
Why?
|
| Monocytes | 2 | 2013 | 277 | 0.400 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 29 | 0.400 |
Why?
|
| Cordyceps | 1 | 2013 | 4 | 0.400 |
Why?
|
| Smad Proteins | 1 | 2013 | 12 | 0.400 |
Why?
|
| Aortic Diseases | 1 | 2013 | 34 | 0.400 |
Why?
|
| Risk Assessment | 1 | 2016 | 863 | 0.400 |
Why?
|
| Pyridones | 1 | 2013 | 50 | 0.400 |
Why?
|
| GB virus C | 1 | 2013 | 2 | 0.390 |
Why?
|
| Dexamethasone | 1 | 2013 | 55 | 0.390 |
Why?
|
| Base Sequence | 6 | 2021 | 983 | 0.390 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 146 | 0.380 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2013 | 140 | 0.380 |
Why?
|
| Fibronectins | 4 | 2017 | 69 | 0.380 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 436 | 0.370 |
Why?
|
| Lysosomes | 3 | 2020 | 86 | 0.370 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1285 | 0.360 |
Why?
|
| Prognosis | 4 | 2020 | 861 | 0.360 |
Why?
|
| Microscopy, Confocal | 4 | 2015 | 224 | 0.350 |
Why?
|
| Polyubiquitin | 1 | 2011 | 7 | 0.350 |
Why?
|
| Hemagglutinins | 1 | 2011 | 9 | 0.340 |
Why?
|
| Cullin Proteins | 3 | 2005 | 12 | 0.340 |
Why?
|
| Blotting, Western | 7 | 2015 | 883 | 0.340 |
Why?
|
| Lipids | 1 | 2013 | 256 | 0.340 |
Why?
|
| Mesoderm | 4 | 2007 | 73 | 0.340 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2021 | 1766 | 0.330 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 20 | 0.330 |
Why?
|
| Myocardium | 1 | 2013 | 263 | 0.330 |
Why?
|
| Rats, Wistar | 3 | 2019 | 283 | 0.330 |
Why?
|
| Heart Failure | 2 | 2024 | 302 | 0.330 |
Why?
|
| Plant Extracts | 1 | 2013 | 302 | 0.310 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 486 | 0.310 |
Why?
|
| Ubiquitination | 1 | 2010 | 62 | 0.310 |
Why?
|
| Heart | 1 | 2011 | 184 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2010 | 96 | 0.310 |
Why?
|
| Glycine | 2 | 2019 | 47 | 0.300 |
Why?
|
| Anemia | 2 | 2019 | 55 | 0.300 |
Why?
|
| Isoquinolines | 2 | 2019 | 55 | 0.300 |
Why?
|
| Hemoglobins | 2 | 2019 | 113 | 0.300 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2015 | 196 | 0.290 |
Why?
|
| DNA Primers | 4 | 2013 | 294 | 0.290 |
Why?
|
| Hyperkalemia | 3 | 2024 | 13 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 287 | 0.280 |
Why?
|
| Simian immunodeficiency virus | 2 | 2010 | 60 | 0.280 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 704 | 0.280 |
Why?
|
| Cell Transdifferentiation | 1 | 2007 | 8 | 0.270 |
Why?
|
| Cell Communication | 2 | 2018 | 114 | 0.270 |
Why?
|
| Vimentin | 2 | 2024 | 44 | 0.270 |
Why?
|
| HIV Infections | 6 | 2024 | 2586 | 0.260 |
Why?
|
| Proteins | 3 | 2004 | 382 | 0.260 |
Why?
|
| Gene Products, gag | 4 | 2004 | 12 | 0.250 |
Why?
|
| Prevalence | 3 | 2016 | 1612 | 0.250 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2853 | 0.250 |
Why?
|
| Ultrasonography | 3 | 2022 | 135 | 0.250 |
Why?
|
| Cytokines | 2 | 2021 | 678 | 0.240 |
Why?
|
| Random Allocation | 2 | 2021 | 147 | 0.240 |
Why?
|
| Cadherins | 4 | 2013 | 102 | 0.240 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 386 | 0.230 |
Why?
|
| Age Distribution | 2 | 2016 | 249 | 0.220 |
Why?
|
| Virus Release | 2 | 2015 | 9 | 0.220 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2017 | 95 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 91 | 0.220 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2024 | 10 | 0.210 |
Why?
|
| Risk Factors | 3 | 2020 | 3994 | 0.210 |
Why?
|
| Hela Cells | 3 | 2015 | 376 | 0.210 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3156 | 0.210 |
Why?
|
| DNA, Viral | 3 | 2024 | 311 | 0.210 |
Why?
|
| Leupeptins | 1 | 2004 | 12 | 0.210 |
Why?
|
| Advisory Committees | 1 | 2024 | 35 | 0.210 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 22 | 0.210 |
Why?
|
| Nucleoside Deaminases | 5 | 2007 | 7 | 0.200 |
Why?
|
| Hot Temperature | 2 | 2014 | 141 | 0.200 |
Why?
|
| Up-Regulation | 2 | 2017 | 536 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 159 | 0.200 |
Why?
|
| Phosphorylation | 2 | 2019 | 986 | 0.200 |
Why?
|
| Calcium-Binding Proteins | 2 | 2016 | 81 | 0.200 |
Why?
|
| Apoptosis | 4 | 2024 | 1568 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2005 | 195 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1455 | 0.200 |
Why?
|
| Incidence | 2 | 2016 | 1078 | 0.190 |
Why?
|
| Hematinics | 2 | 2019 | 9 | 0.190 |
Why?
|
| Quercetin | 1 | 2023 | 46 | 0.190 |
Why?
|
| Protein Transport | 2 | 2014 | 296 | 0.190 |
Why?
|
| Transcriptional Activation | 1 | 2023 | 173 | 0.190 |
Why?
|
| Area Under Curve | 2 | 2014 | 95 | 0.190 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 35 | 0.180 |
Why?
|
| ROC Curve | 2 | 2014 | 159 | 0.180 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2013 | 59 | 0.180 |
Why?
|
| Aortic Valve | 1 | 2022 | 38 | 0.180 |
Why?
|
| Ergocalciferols | 1 | 2021 | 6 | 0.180 |
Why?
|
| Young Adult | 4 | 2021 | 5080 | 0.180 |
Why?
|
| Chemokine CCL21 | 1 | 2021 | 14 | 0.180 |
Why?
|
| Phosphorus | 1 | 2022 | 65 | 0.180 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 51 | 0.180 |
Why?
|
| Caspase 8 | 1 | 2021 | 32 | 0.180 |
Why?
|
| Chemokines | 1 | 2022 | 96 | 0.180 |
Why?
|
| Necrosis | 1 | 2021 | 54 | 0.180 |
Why?
|
| Tight Junctions | 1 | 2021 | 27 | 0.180 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 28 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2020 | 2544 | 0.170 |
Why?
|
| Rats, Inbred SHR | 2 | 2011 | 30 | 0.170 |
Why?
|
| 3' Untranslated Regions | 1 | 2021 | 82 | 0.170 |
Why?
|
| Cyclin B1 | 1 | 2021 | 18 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 200 | 0.170 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 19 | 0.170 |
Why?
|
| G2 Phase | 1 | 2021 | 28 | 0.170 |
Why?
|
| Cell Division | 2 | 2021 | 311 | 0.170 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2021 | 76 | 0.170 |
Why?
|
| Muscle, Smooth | 3 | 2012 | 58 | 0.170 |
Why?
|
| Ligands | 1 | 2022 | 388 | 0.170 |
Why?
|
| Ischemia | 1 | 2021 | 47 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 213 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 68 | 0.170 |
Why?
|
| Caspase 3 | 1 | 2021 | 227 | 0.170 |
Why?
|
| Repressor Proteins | 5 | 2007 | 273 | 0.170 |
Why?
|
| Cell Death | 1 | 2021 | 278 | 0.160 |
Why?
|
| Tissue Distribution | 1 | 2021 | 240 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2021 | 126 | 0.160 |
Why?
|
| Albumins | 1 | 2020 | 33 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 152 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 93 | 0.160 |
Why?
|
| Hiccup | 1 | 2019 | 1 | 0.160 |
Why?
|
| Total Lung Capacity | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cholesterol | 3 | 2019 | 232 | 0.160 |
Why?
|
| Dyspnea | 1 | 2019 | 22 | 0.160 |
Why?
|
| DNA Damage | 1 | 2022 | 356 | 0.160 |
Why?
|
| Epoetin Alfa | 1 | 2019 | 2 | 0.150 |
Why?
|
| Plasmids | 2 | 2013 | 244 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 611 | 0.150 |
Why?
|
| Hypertension | 2 | 2024 | 835 | 0.150 |
Why?
|
| Smad2 Protein | 1 | 2019 | 11 | 0.150 |
Why?
|
| Cyclohexylamines | 1 | 2019 | 14 | 0.150 |
Why?
|
| Peptides | 2 | 2021 | 372 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1124 | 0.150 |
Why?
|
| Fatigue | 1 | 2019 | 100 | 0.150 |
Why?
|
| Adenine | 1 | 2019 | 46 | 0.150 |
Why?
|
| Insulin Resistance | 1 | 2021 | 201 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 423 | 0.150 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 60 | 0.150 |
Why?
|
| Antigen Presentation | 1 | 2018 | 58 | 0.140 |
Why?
|
| Benzamides | 1 | 2019 | 81 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 694 | 0.140 |
Why?
|
| Biological Transport | 1 | 2018 | 204 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 30 | 0.140 |
Why?
|
| Virus Internalization | 1 | 2018 | 36 | 0.140 |
Why?
|
| Organophosphorus Compounds | 1 | 2018 | 37 | 0.140 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 40 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 934 | 0.140 |
Why?
|
| Serum Albumin, Bovine | 1 | 2018 | 49 | 0.130 |
Why?
|
| Piperidines | 1 | 2018 | 83 | 0.130 |
Why?
|
| Enzyme Activation | 2 | 2016 | 462 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2017 | 35 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 51 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2018 | 154 | 0.130 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2016 | 11 | 0.130 |
Why?
|
| Phenotype | 2 | 2016 | 780 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 125 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1067 | 0.120 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2009 | 54 | 0.120 |
Why?
|
| Cause of Death | 1 | 2016 | 186 | 0.120 |
Why?
|
| Lentiviruses, Primate | 2 | 2005 | 2 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 136 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 2 | 2005 | 8 | 0.120 |
Why?
|
| Coculture Techniques | 2 | 2013 | 109 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2015 | 17 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 518 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2020 | 1759 | 0.110 |
Why?
|
| RNA, Viral | 2 | 2014 | 321 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2015 | 35 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2016 | 210 | 0.110 |
Why?
|
| Hypertrophy | 2 | 2005 | 34 | 0.110 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 63 | 0.110 |
Why?
|
| Enzyme Stability | 1 | 2014 | 34 | 0.110 |
Why?
|
| Streptococcus | 1 | 2014 | 18 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2006 | 346 | 0.110 |
Why?
|
| Antioxidants | 1 | 2018 | 443 | 0.110 |
Why?
|
| Point Mutation | 1 | 2014 | 98 | 0.110 |
Why?
|
| Endosomes | 1 | 2014 | 33 | 0.110 |
Why?
|
| Ultracentrifugation | 1 | 2013 | 14 | 0.100 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2013 | 35 | 0.100 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2013 | 29 | 0.100 |
Why?
|
| Cell Movement | 1 | 2018 | 655 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 11 | 0.100 |
Why?
|
| Golgi Apparatus | 1 | 2013 | 27 | 0.100 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2013 | 13 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2014 | 224 | 0.100 |
Why?
|
| Registries | 1 | 2016 | 437 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 148 | 0.100 |
Why?
|
| S Phase | 1 | 2013 | 36 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 152 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 256 | 0.100 |
Why?
|
| Serum Amyloid A Protein | 1 | 2013 | 14 | 0.100 |
Why?
|
| Limit of Detection | 1 | 2013 | 94 | 0.100 |
Why?
|
| Age Factors | 1 | 2016 | 1154 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 760 | 0.100 |
Why?
|
| Endothelium | 1 | 2013 | 28 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 59 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 108 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 440 | 0.100 |
Why?
|
| Glycosylation | 1 | 2013 | 113 | 0.090 |
Why?
|
| Triglycerides | 1 | 2013 | 147 | 0.090 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 3 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 201 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 587 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 638 | 0.090 |
Why?
|
| Health Surveys | 1 | 2014 | 405 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2012 | 64 | 0.090 |
Why?
|
| Biopsy | 1 | 2012 | 177 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2006 | 307 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2013 | 238 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2013 | 206 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 334 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 1542 | 0.090 |
Why?
|
| Actinin | 1 | 2011 | 5 | 0.090 |
Why?
|
| Sialoglycoproteins | 1 | 2011 | 14 | 0.090 |
Why?
|
| Desmin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 241 | 0.090 |
Why?
|
| Jurkat Cells | 3 | 2009 | 87 | 0.090 |
Why?
|
| Rats, Inbred WKY | 1 | 2011 | 17 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2024 | 665 | 0.090 |
Why?
|
| Viral Load | 1 | 2013 | 348 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 72 | 0.090 |
Why?
|
| Creatinine | 1 | 2011 | 102 | 0.080 |
Why?
|
| Aging | 1 | 2016 | 783 | 0.080 |
Why?
|
| Logistic Models | 1 | 2014 | 1009 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 187 | 0.080 |
Why?
|
| Time Factors | 2 | 2016 | 1857 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2014 | 363 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 210 | 0.080 |
Why?
|
| Prostate | 1 | 2011 | 155 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 41 | 0.080 |
Why?
|
| Echocardiography | 1 | 2011 | 167 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 116 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 296 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 1234 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2010 | 114 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2013 | 638 | 0.080 |
Why?
|
| Recombination, Genetic | 2 | 2007 | 95 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 760 | 0.080 |
Why?
|
| Arrestins | 1 | 2009 | 28 | 0.080 |
Why?
|
| Cisplatin | 2 | 2022 | 98 | 0.070 |
Why?
|
| COS Cells | 3 | 2004 | 68 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2019 | 317 | 0.070 |
Why?
|
| Morphine | 1 | 2009 | 69 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2009 | 124 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1081 | 0.070 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Signal Recognition Particle | 1 | 2007 | 6 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 541 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 95 | 0.070 |
Why?
|
| Integrases | 1 | 2007 | 28 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2011 | 666 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 512 | 0.070 |
Why?
|
| HIV Integrase | 1 | 2007 | 22 | 0.060 |
Why?
|
| Virus Integration | 1 | 2007 | 65 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 41 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 26 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 2011 | 1180 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 211 | 0.060 |
Why?
|
| Adolescent | 1 | 2016 | 6081 | 0.060 |
Why?
|
| Genetic Vectors | 2 | 2002 | 165 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2003 | 411 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2004 | 12 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2005 | 168 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 34 | 0.050 |
Why?
|
| Sequence Deletion | 2 | 2008 | 93 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 48 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 48 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 78 | 0.050 |
Why?
|
| Mitogens | 1 | 2003 | 10 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 69 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 64 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2003 | 159 | 0.050 |
Why?
|
| Cell Separation | 1 | 2003 | 94 | 0.050 |
Why?
|
| Endocytosis | 1 | 2024 | 118 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 116 | 0.050 |
Why?
|
| Sindbis Virus | 1 | 2002 | 14 | 0.050 |
Why?
|
| Gene Products, env | 1 | 2002 | 23 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 58 | 0.050 |
Why?
|
| Genomic Instability | 1 | 2022 | 37 | 0.050 |
Why?
|
| Aquaporin 2 | 1 | 2021 | 1 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 239 | 0.040 |
Why?
|
| Sulfones | 1 | 2021 | 47 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 310 | 0.040 |
Why?
|
| Nitriles | 1 | 2021 | 81 | 0.040 |
Why?
|
| Protein Binding | 2 | 2008 | 1082 | 0.040 |
Why?
|
| Ecosystem | 1 | 2022 | 175 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2002 | 129 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2020 | 12 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2021 | 160 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 175 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2020 | 18 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2000 | 24 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2000 | 26 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 526 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2000 | 76 | 0.040 |
Why?
|
| Capsid | 1 | 2000 | 65 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 97 | 0.040 |
Why?
|
| Acidosis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2002 | 430 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2000 | 190 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1377 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 706 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1600 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 575 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2013 | 269 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 53 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 712 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 232 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 65 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 127 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2016 | 128 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2676 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 671 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 189 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 374 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 237 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 197 | 0.020 |
Why?
|
| U937 Cells | 1 | 2011 | 31 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 49 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 299 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 280 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 209 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2005 | 735 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 2009 | 52 | 0.020 |
Why?
|
| Genes, gag | 1 | 2008 | 5 | 0.020 |
Why?
|
| Leucine Zippers | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pancreas | 1 | 2007 | 45 | 0.020 |
Why?
|
| Reverse Transcription | 1 | 2007 | 23 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 148 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 968 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 8 | 0.020 |
Why?
|
| Gene Products, vpr | 1 | 2006 | 5 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 157 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2009 | 252 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 352 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2006 | 113 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 97 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 127 | 0.010 |
Why?
|
| Fusion Proteins, gag-pol | 1 | 2004 | 2 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 219 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 272 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 14 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 154 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1092 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 267 | 0.010 |
Why?
|
| Phylogeny | 1 | 2005 | 769 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2000 | 26 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2000 | 13 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 32 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2000 | 75 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 107 | 0.010 |
Why?
|
| Ovary | 1 | 2000 | 113 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 458 | 0.010 |
Why?
|